ERROR! No headcode.htm file found.

Bio

Clinical Focus


  • Fellow

Honors & Awards


  • Pfizer/ACMGF Next Generation Clinical Laboratory Biochemical Genetics Fellowship Award, American College of Medical Genetics (2021)
  • Henry Christian Award, American Federation for Medical Research (AFMR) (2020)
  • Outstanding Recent Biochemistry Undergraduate Alumni Award, Virginia Tech (2018)
  • J. Edmund and Kathryn S. Bradley Award for Excellence in Pediatrics, University of Maryland School of Medicine (2018)
  • Commencement Speaker for Epidemiology and Human Genetics Graduate Program, University of Maryland School of Medicine (2016)
  • 2016 PhD Thesis of the Year Award, Graduate Program in Life Sciences, University of Maryland School of Medicine (2016)

Publications

All Publications


  • Medical genetics training in the COVID-19 era: A resident's perspective. American journal of medical genetics. Part A Tise, C. G. 2021

    View details for DOI 10.1002/ajmg.a.62379

    View details for PubMedID 34096675

  • Aicardi-Goutičres syndrome may present with positive newborn screen for X-linked adrenoleukodystrophy. American journal of medical genetics. Part A Tise, C. G., Morales, J. A., Lee, A. S., Velez-Bartolomei, F. n., Floyd, B. J., Levy, R. J., Cusmano-Ozog, K. P., Feigenbaum, A. S., Ruzhnikov, M. R., Lee, C. U., Enns, G. M. 2021

    Abstract

    We report three unrelated probands, two male and one female, diagnosed with Aicardi-Goutičres syndrome (AGS) after screening positive on California newborn screening (CA NBS) for X-linked adrenoleukodystrophy (X-ALD) due to elevated C26:0 lysophosphatidylcholine (C26:0-LPC). Follow-up evaluation was notable for elevated C26:0, C26:1, and C26:0/C22:0 ratio, and normal red blood cell plasmalogens levels in all three probands. Diagnoses were confirmed by molecular sequencing prior to 12?months of age after clinical evaluation was inconsistent with X-ALD or suggestive of AGS. For at least one proband, the early diagnosis of AGS enabled candidacy for enrollment into a therapeutic clinical trial. This report demonstrates the importance of including AGS on the differential diagnosis for individuals who screen positive for X-ALD, particularly infants with abnormal neurological features, as this age of onset would be highly unusual for X-ALD. While AGS is not included on the Recommended Universal Screening Panel, affected individuals can be identified early through state NBS programs so long as providers are aware of a broader differential that includes AGS. This report is timely, as state NBS algorithms for X-ALD are actively being established, implemented, and refined.

    View details for DOI 10.1002/ajmg.a.62160

    View details for PubMedID 33683010

  • Profound neonatal lactic acidosis and renal tubulopathy in a patient with glycogen storage disease type IX?2 secondary to a de novo pathogenic variant in PHKA2. Molecular genetics and metabolism reports Morales, J. A., Tise, C. G., Narang, A., Grimm, P. C., Enns, G. M., Lee, C. U. 2021; 27: 100765

    Abstract

    The phenotype of individuals with glycogen storage disease (GSD) IX appears to be highly variable, even within subtypes. Features include short stature, fasting hypoglycemia with ketosis, hepatomegaly, and transaminitis. GSD IX?2 is caused by hemizygous pathogenic variants in PHKA2, and results in deficiency of the phosphorylase kinase enzyme, particularly in the liver. Like other GSDs, GSD IX?2 can present with hypoglycemia and post-prandial lactic acidosis, but has never been reported in a newborn, nor with lactic acidosis as the presenting feature. Here we describe the clinical presentation and course of a newborn boy with profound neonatal lactic and metabolic acidosis, renal tubulopathy, and sensorineural hearing loss (SNHL) diagnosed with GSD IX?2 through exome sequencing. Review of the literature suggests this case represents an atypical and severe presentation of GSD IX?2 and proposes expansion of the phenotype to include neonatal lactic acidosis and renal tubulopathy.

    View details for DOI 10.1016/j.ymgmr.2021.100765

    View details for PubMedID 34277355

    View details for PubMedCentralID PMC8261893

  • Genetics of recurrent pregnancy loss: a review. Current opinion in obstetrics & gynecology Tise, C. G., Byers, H. M. 2021

    Abstract

    Human reproduction is remarkably inefficient; with pregnancy loss occurring in 10-30% of clinically recognized pregnancies. Of those, 3-5% of couples experience recurrent pregnancy loss (RPL), more than 50% of who never receive an underlying diagnosis. Herein, we review evidence that genetic changes, including pathogenic variant(s) in highly penetrant genes, may provide an explanation for a proportion of couples with pregnancy loss.Genetic abnormalities that may predispose to pregnancy loss include chromosomal aneuploidy, copy number variants, single-gene changes and others. Although previously limited by the need for hypothesis-driven assessment, advancement of various molecular technologies have sheparded in the opportunity to identify molecular cause of highly heterogeneous conditions, including RPL. The identification of causative genetic aberrations associated with RPL demonstrates a promising area of further research.The journey of human development from a single-cell zygote to a term infant is complex process. Early research into copy number variants and highly penetrant single-gene changes may provide diagnosis for a proportion of couples with RPL as well as inform genes critical for early human development.

    View details for DOI 10.1097/GCO.0000000000000695

    View details for PubMedID 33605623

  • Case 1: Rapidly Rising Bilirubin Level in a 3-day-old Term Infant. NeoReviews Tise, C. G., Joshi, N. S., Erice-Taganas, A. D., Blecharczyk, E. M. 2020; 21 (10): e687?e690

    View details for DOI 10.1542/neo.21-10-e687

    View details for PubMedID 33004562

  • nonsense variants on DHEA homeostasis. Molecular genetics and metabolism reports Tise, C. G., Anforth, L. E., Zhou, A. E., Perry, J. A., McArdle, P. F., Streeten, E. A., Shuldiner, A. R., Yerges-Armstrong, L. M. 2017; 10: 84-91

    Abstract

    Sulfate is critical in the biotransformation of multiple compounds via sulfation. These compounds include neurotransmitters, proteoglycans, xenobiotics, and hormones such as dehydroepiandrosterone (DHEA). Sulfation reactions are thought to be rate-limited by endogenous sulfate concentrations. The gene, SLC13A1, encodes the sodium-sulfate cotransporter NaS1, responsible for sulfate (re)absorption in the intestines and kidneys. We previously reported two rare, non-linked, nonsense variants in SLC13A1 (R12X and W48X) associated with hyposulfatemia (P = 9 × 10- 20).To examine the effect of serum sulfate concentration and sulfate-lowering genotype on DHEA homeostasis.Retrospective cohort study.Academic research.Participants of the Amish Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study and the Amish Hereditary and Phenotype Intervention (HAPI) Study.DHEA, DHEA-S, and DHEA-S/DHEA ratio.Increased serum sulfate was associated with decreased DHEA-S (P = 0.03) and DHEA-S/DHEA ratio (P = 0.06) in males but not females. Female SLC13A1 nonsense variant carriers, who had lower serum sulfate (P = 9 × 10- 13 ), exhibited 14% lower DHEA levels (P = 0.01) and 7% higher DHEA-S/DHEA ratios compared to female non-carriers (P = 0.002). Consistent with this finding, female SLC13A1 nonsense variant carriers also had lower total testosterone levels compared to non-carrier females (P = 0.03).Our results demonstrate an inverse relationship between serum sulfate, and DHEA-S and DHEA-S/DHEA ratio in men, while also suggesting that the sulfate-lowering variants, SLC13A1 R12X and W48X, decrease DHEA and testosterone levels, and increase DHEA-S/DHEA ratio in women. While paradoxical, these results illustrate the complexity of the mechanisms involved in DHEA homeostasis and warrant additional studies to better understand sulfate's role in hormone physiology.

    View details for DOI 10.1016/j.ymgmr.2017.01.005

    View details for PubMedID 28154797

    View details for PubMedCentralID PMC5278115

  • Are Patients with Psychogenic Movement Disorders More Likely to be Healthcare Workers? MOVEMENT DISORDERS CLINICAL PRACTICE Perry, C. G., Holmes, K. G., Gruber-Baldini, A. L., Anderson, K. E., Shulman, L. M., Weiner, W. J., Reich, S. G. 2017; 4 (1): 62?67

    View details for DOI 10.1002/mdc3.12351

    View details for Web of Science ID 000396370400014

  • From Genotype to Phenotype: Nonsense Variants in SLC13A1 Are Associated with Decreased Serum Sulfate and Increased Serum Aminotransferases G3-GENES GENOMES GENETICS Tise, C. G., Perry, J. A., Anforth, L. E., Pavlovich, M. A., Backman, J. D., Ryan, K. A., Lewis, J. P., O'Connell, J. R., Yerges-Armstrong, L. M., Shuldiner, A. R. 2016; 6 (9): 2909-2918

    Abstract

    Using genomic applications to glean insights into human biology, we systematically searched for nonsense single nucleotide variants (SNVs) that are rare in the general population but enriched in the Old Order Amish (Amish) due to founder effect. We identified two nonlinked, nonsense SNVs (R12X and W48X) in SLC13A1 (allele frequencies 0.29% and 0.74% in the Amish; enriched 1.2-fold and 3.7-fold, compared to the outbred Caucasian population, respectively). SLC13A1 encodes the apical sodium-sulfate cotransporter (NaS1) responsible for sulfate (re)absorption in the kidneys and intestine. SLC13A1 R12X and W48X were independently associated with a 27.6% (P = 2.7 × 10(-8)) and 27.3% (P = 6.9 × 10(-14)) decrease in serum sulfate, respectively (P = 8.8 × 10(-20) for carriers of either SLC13A1 nonsense SNV). We further performed the first exome- and genome-wide association study (ExWAS/GWAS) of serum sulfate and identified a missense variant (L348P) in SLC26A1, which encodes the basolateral sulfate-anion transporter (Sat1), that was associated with decreased serum sulfate (P = 4.4 × 10(-12)). Consistent with sulfate's role in xenobiotic detoxification and protection against acetaminophen-induced hepatotoxicity, SLC13A1 nonsense SNV carriers had higher aminotransferase levels compared to noncarriers. Furthermore, SLC26A1 L348P was associated with lower whole-body bone mineral density (BMD) and higher serum calcium, consistent with the osteochondrodysplasia exhibited by dogs and sheep with naturally occurring, homozygous, loss-of-function mutations in Slc13a1 This study demonstrates the power and translational potential of systematic identification and characterization of rare, loss-of-function variants and warrants additional studies to better understand the importance of sulfate in human physiology, disease, and drug toxicity.

    View details for DOI 10.1534/g3.116.032979

    View details for Web of Science ID 000384021400022

    View details for PubMedID 27412988

    View details for PubMedCentralID PMC5015947

  • Educational Innovations in Clinical Pharmacogenomics CLINICAL PHARMACOLOGY & THERAPEUTICS Perry, C. G., Maloney, K. A., Beitelshees, A. L., Jeng, L. J., Ambulos, N. P., Shuldiner, A. R., Blitzer, M. G. 2016; 99 (6): 582-584

    Abstract

    Genetic and genomic discovery is revolutionizing medicine at an extraordinary pace, leading to a better understanding of disease and improved treatments for patients. This advanced pace of discovery presents an urgency to expand medical school curricula to include genetic and genomic testing (including pharmacogenomics), and integration of genomic medicine into clinical practice. Consequently, organizations and healthcare authorities have charged medical schools with training future physicians to be competent in their knowledge of genomic implementation.

    View details for DOI 10.1002/cpt.352

    View details for Web of Science ID 000376246600016

    View details for PubMedID 26875057

  • Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT: pharmacometrics & systems pharmacology Ellero-Simatos, S., Lewis, J. P., Georgiades, A., Yerges-Armstrong, L. M., Beitelshees, A. L., Horenstein, R. B., Dane, A., Harms, A. C., Ramaker, R., Vreeken, R. J., Perry, C. G., Zhu, H., Sŕnchez, C. L., Kuhn, C., Ortel, T. L., Shuldiner, A. R., Hankemeier, T., Kaddurah-Daouk, R. 2014; 3

    Abstract

    While aspirin is generally effective for prevention of cardiovascular disease, considerable variation in drug response exists, resulting in some individuals displaying high on-treatment platelet reactivity. We used pharmacometabolomics to define pathways implicated in variation of response to treatment. We profiled serum samples from healthy subjects pre- and postaspirin (14 days, 81?mg/day) using mass spectrometry. We established a strong signature of aspirin exposure independent of response (15/34 metabolites changed). In our discovery (N = 80) and replication (N = 125) cohorts, higher serotonin levels pre- and postaspirin correlated with high, postaspirin, collagen-induced platelet aggregation. In a third cohort, platelets from subjects with the highest levels of serotonin preaspirin retained higher reactivity after incubation with aspirin than platelets from subjects with the lowest serotonin levels preaspirin (72?±?8 vs. 61?±?11%, P = 0.02, N = 20). Finally, ex vivo, serotonin strongly increased platelet reactivity after platelet incubation with aspirin (+20%, P = 4.9?×?10(-4), N = 12). These results suggest that serotonin is implicated in aspirin response variability.

    View details for DOI 10.1038/psp.2014.22

    View details for PubMedID 25029353

    View details for PubMedCentralID PMC4120016

  • Pharmacogenomics of Anti-platelet and Anti-coagulation Therapy CURRENT CARDIOLOGY REPORTS Fisch, A. S., Perry, C. G., Stephens, S. H., Horenstein, R. B., Shuldiner, A. R. 2013; 15 (7)

    Abstract

    Arterial thrombosis is a major component of vascular disease, especially myocardial infarction (MI) and stroke. Current anti-thrombotic therapies such as warfarin and clopidogrel are effective in inhibiting cardiovascular events; however, there is great inter-individual variability in response to these medications. In recent years, it has been recognized that genetic factors play a significant role in drug response, and, subsequently, common variants in genes responsible for metabolism and drug action have been identified. These discoveries along with new diagnostic targets and therapeutic strategies hold promise for more effective individualized anti-coagulation and anti-platelet therapy.

    View details for DOI 10.1007/s11886-013-0381-3

    View details for Web of Science ID 000345083100009

    View details for PubMedID 23797323

    View details for PubMedCentralID PMC3809070

  • Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? JOURNAL OF HUMAN GENETICS Perry, C. G., Shuldiner, A. R. 2013; 58 (6): 339-345

    Abstract

    Pharmacogenomics, the study of the genomics of drug response and adverse effects, holds great promise for more effective individualized (personalized) medicine. Recent evidence supports a role of loss-of-function (LOF) variants in the cytochrome P450 enzyme CYP2C19 as a determinant of clopidogrel response. Patients given clopidogrel after percutaneous coronary intervention who carry LOF variants do not metabolize clopidogrel, a prodrug, into its active form resulting in decreased inhibition of platelet function and a higher likelihood of recurrent cardiovascular events. Despite a large body of evidence supporting clinical utility, adoption of anti-platelet pharmacogenetics into clinical practice has been slow. In this review, we summarize the pharmacokinetic, pharmacodynamic and clinical evidence, identify gaps in knowledge and other barriers that appear to be slowing adoption, and describe CYP2C19 pharmacogenetics implementation projects currently underway. Only when we surmount these barriers will clinicians be able to use pharmacogenetic information in conjunction with the history, physical examination and other medical tests and information to choose the most efficacious anti-platelet therapy for each individual patient.

    View details for DOI 10.1038/jhg.2013.41

    View details for Web of Science ID 000320843600007

    View details for PubMedID 23697979

    View details for PubMedCentralID PMC3715315

Stanford Medicine Resources: